ERBB2 and cancer: Trastuzumab, a human epidermal growth factor receptor 2 (HER2)-targeted therapy, is a major cause of cancer therapy-related cardiac dysfunction (CTRCD), with decreased left ventricular ejection fraction (LVEF) in 25% of cases and symptomatic heart failure in 0.8–4.0% of cases [1–4].